Toronto Memory Program

Dr. Sharon Cohen, Medical Director of Toronto Memory Program, joined the shoelace-tying ceremony at the Walk for Alzheimer’s this past weekend in Toronto, helping kick off a day dedicated to raising awareness, supporting families, and advancing the fight against dementia. We are proud to stand alongside our community in support of those affected by Alzheimer’s disease and other forms of dementia.

This Clinical Trials Day, our team at Headlands Toronto Memory Program is celebrating the resilience, passion, and purpose that keep research moving forward. The 2026 theme, “Research Rising,” recognizes the dedication of clinical research professionals who continue to adapt, innovate, and persevere in pursuit of better outcomes for patients everywhere.

https://youtu.be/kkaKRfjMvf8

Clinical Trials Day 2026 | Headlands Toronto Memory Program This Clinical Trials Day, the team at Headlands Toronto Memory Program is celebrating the resilience, passion, and purpose that keep research moving forward....

Health Canada has approved a second drug that can slow the progression of Alzheimer’s disease.

The drug “provides an important opportunity for early patients to maintain their independence,” said Dr. Sharon Cohen, neurologist and medical director at Toronto Memory Program.

‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s - National | Globalnews.ca This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved lecanemab, commercially known as Leqembi, in October 2025.

Today, after more than 35 years of commitment to advancing Alzheimer's research, Lilly Canada announced Health Canada's approval of Kisunla (donanemab). Kisunla is approved as a once-monthly treatment for people living with early symptomatic Alzheimer's disease. Kisunla is indicated for the treatment of adults with a clinical diagnosis of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, who are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers, and have confirmed amyloid pathology. In addition to Canada, Kisunla is approved in 48 markets, globally.

"Changing the downward trajectory of Alzheimer's disease is of the utmost importance. Individuals at early stages of this disease live in their own homes and lead robust lives but often dread what is to come. Kisunla provides an important opportunity for early patients to maintain their independence, continue to engage in activities that they value, and to have a greater sense of hopefulness about their future." Dr. Sharon, Cohen, neurologist and medical director, Toronto Memory Program community-based medical facility.

HEALTH CANADA AUTHORIZES LILLY'S KISUNLA™ (DONANEMAB), A NEW TREATMENT FOR EARLY ALZHEIMER'S DISEASE /CNW/ - Today, after more than 35 years of commitment to advancing Alzheimer's research, Lilly Canada announced Health Canada's approval of Kisunla™...

The weather is warming up—spring is a great time to get outside!

Even a short 10–15 minute walk can:
✔️ Boost mood
✔️ Support memory
✔️ Improve sleep

Regular walking has been shown to support brain health and overall well-being in older adults.

Tip: Try walking at the same time each day to build a healthy routine.

Learn more:

Physical activity and the risk of dementia Regular physical activity is one of the best things that you can do to reduce your risk of developing dementia.

The IG Wealth Management Walk for Alzheimer’s in Toronto will take place on Saturday, May 30, 2026 at Orchard Pavilion, Downsview Park. This annual event brings the community together to support people living with dementia, as well as their families and care partners.

We are proud to share that Dr. Sharon Cohen of Toronto Memory Program will participate in the opening ceremonies, completing the symbolic shoelace-tying kickoff.

Organized by the Alzheimer Society of Toronto, the Walk raises essential funds for local programs and services while promoting physical activity for brain health.

Walk Join the Walk for Alzheimer's to support those living with dementia and make a difference in your community.

Earlier this month, Toronto Memory Program was truly privileged to host a lunch in appreciation of our Alzheimer’s disease prevention clinical trial participants. It was an opportunity to share hopeful and exciting updates in Alzheimer’s disease and to recognize the significant contributions of each participant and study partner to prevention research. The energy in the room said it all—there’s real power in moving research forward together. We’re incredibly lucky to support this community.

Wondering whether memory changes are normal aging or something more?

Through BrightFocus Foundation, Dr. Sharon Cohen, Behavioral Neurologist and Medical Director of Toronto Memory Program, discusses the early signs and symptoms of Alzheimer’s disease, conditions that can mimic dementia, and how to start the conversation with your doctor.

Watch “Is It Alzheimer’s? Recognizing Early Signs & Symptoms” to learn why early evaluation matters and what to look for.

Is It Alzheimer’s? Recognizing Early Signs & Symptoms Behavioral neurologist Dr. Sharon Cohen explains the early signs and symptoms of Alzheimer’s disease, medical conditions that can mimic dementia, and how to start a conversation with your doctor.

Making smart food choices is an important part of healthy aging.

Understanding the different food groups — and how much of each should make up your diet — can help you form a healthy eating pattern over time.

It is important to get the recommended amount of each food group without going over your daily recommended calories. Keep in mind that the amount you should eat to maintain your weight depends on your age, s*x, and level of physical activity.

Healthy Eating As You Age: Know Your Food Groups How to eat healthy? Choose a variety of nutrient-dense foods across and within all the food groups: vegetables, fruits, grains, protein foods, dairy products, and oils.

Alzheimer’s disease research is moving faster than ever.

With over 150+ drugs currently in development and new breakthroughs in biomarkers, prevention trials, and combination therapies, the future of treatment is changing in real time.

🎧 Want to hear directly from experts? Listen to this podcast featuring Dr. Jeffrey Cummings for an insider’s look at what’s coming next.

Thinking about clinical trials? Now is the time to get informed and get involved.

Alzheimer’s Clinical Trials 2026: An Insider’s Look with Dr. Jeffrey Cummings Join Dr. Jeffrey Cummings as he shares an insider’s overview of the evolving Alzheimer’s treatment development pipeline.